Cedar Pollen Allergy - Pipeline Review, H2 2016; New Report Launched
Cedar Pollen Allergy pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Cedar Pollen Allergy – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
View full press release